New Disease-Modifying Therapy Brings Good News for Early-Stage Alzheimer's Patients
July 03, 2024
July 03, 2024
WASHINGTON, July 3 (TNSres) -- UsAgainstAlzheimer's, an organization that says it advocates for research that will speed treatments and drive changes that matter most to people living with Alzheimer's disease, issued the following news release on July 2, 2024:
Early-stage Alzheimer's patients have another choice in slowing their disease today, with U.S. Food and Drug Administration (FDA) approval of donanemab. UsAgainstAlzheimer's celebrates this new choice for patients. The study s . . .
Early-stage Alzheimer's patients have another choice in slowing their disease today, with U.S. Food and Drug Administration (FDA) approval of donanemab. UsAgainstAlzheimer's celebrates this new choice for patients. The study s . . .